Multivalent presentation of antihantavirus peptides on nanoparticles enhances infection blockade

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 6, 2008, Pages 2079-2088

  Hall, Pamela R ^a   Hjelle, Brian ^a   Brown, David C ^a   Ye, Chunyan ^a   Bondu Hawkins, Virginie ^a   Kilpatrick, Kathleen A ^a   Larson, Richard S ^a,b  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINYLGLUTAMINYLALANYLTHREONYLTHREONYLALANYLARGINYLASPARAGINYLCYSTEINYLAMIDE; CYSTEINYLLEUCYLVALYLARGINYLASPARAGINYLLEUCYLALANYLTRYPTOPHYLCYSTEINYLAMIDE; MEMBRANE PROTEIN; NANOPARTICLE; NONAPEPTIDE; VIRUS GLYCOPROTEIN; VIRUS RECEPTOR;

ANTIVIRAL ACTIVITY; ARTICLE; CARDIOPULMONARY INSUFFICIENCY; CARDIOPULMONARY SYNDROME; HANTAVIRUS; IN VITRO STUDY; INFECTION PREVENTION; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIN NOMBRE VIRUS; VIRUS CELL INTERACTION; VIRUS ENTRY;

AMINO ACID SEQUENCE; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; HUMANS; MODELS, MOLECULAR; NANOPARTICLES; PEPTIDE LIBRARY; PEPTIDES, CYCLIC; SIN NOMBRE VIRUS; VERO CELLS;

EID: 44449127068     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01415-07     Document Type: Article

References (51)

1. Ahmad, Z., S. Sharma, and G. K. Khuller. 2007. Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis. Nanomedicine 3:239-243.
2. Baudouin, V., A. Crusiaux, E. Haddad, L. Schandene, M. Goldman, C. Loirat, and D. Abramowicz. 2003. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation 76:459-463.
3. Bender, A. R., H. von Briesen, J. Kreuter, I. B. Duncan, and H. Rubsamen-Waigmann. 1996. Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrob. Agents Chemother. 40:1467-1471.
4. Bharadwaj, M., C. R. Lyons, I. A. Wortman, and B. Hjelle. 1999. Intramuscular inoculation of Sin Nombre hantavirus cDNAs induces cellular and humoral immune responses in BALB/c mice. Vaccine 17:2836-2843.
5. Botten, J., K. Mirowsky, D. Kusewitt, M. Bharadwaj, J. Yee, R. Ricci, R. M. Feddersen, and B. Hjelle. 2000. Experimental infection model for Sin Nombre hantavirus in the deer mouse (Peromyscus maniculatus). Proc. Natl. Acad. Sci. USA 97:10578-10583.
6. De Oliveira, E., J. Villen, E. Giralt, and D. Andreu. 2003. Synthetic approaches to multivalent lipopeptide dendrimers containing cyclic disulfide epitopes of foot-and-mouth disease virus. Bioconjug. Chem. 14:144-152.
7. Dwyer, J. J., K. L. Wilson, D. K. Davison, S. A. Freel, J. E. Seedorff, S. A. Wring, N. A. Tvermoes, T. J. Matthews, M. L. Greenberg, and M. K. Delmedico. 2007. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc. Natl. Acad. Sci. USA 104:12772-12777.
8. Franklin, M. C., S. Kadkhodayan, H. Ackerly, D. Alexandra, M. D. Distefano, L. O. Elliott, J. A. Flygare, G. Mausisa, D. C. Okawa, D. Ong, D. Vucic, K. Deshayes, and W. J. Fairbrother. 2003. Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP). Biochemistry 42:8223-8231.
9. Gauvreau, G. M., A. B. Becker, L. P. Boulet, J. Chakir, R. B. Fick, W. L. Greene, K. J. Killian, P. M. O'byrne, J. K. Reid, and D. W. Cockcroft. 2003. The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J. Allergy Clin. Immunol. 112:331-338.
10. 3 integrins. J. Virol. 73:3951-3959.
11. Hall, P. R., L. Malone, L. O. Sillerud, C. Ye, B. L. Hjelle, and R. S. Larson. 2007. Characterization and NMR solution structure of a novel cyclic pentapeptide inhibitor of pathogenic hantaviruses. Chem. Biol. Drug Des. 69:180-190.
12. Haywood, A. M. 1994. Virus receptors: binding, adhesion strengthening, and changes in viral structure. J. Virol. 68:1-5.
13. Henikoff, S., and J. G. Henikoff. 1992. Amino acid substitution matrices from protein blocks. Proc. Natl. Acad. Sci. USA 89:10915-10919.
14. Hetian, L., A. Ping, S. Shumei, L. Xiaoying, H. Luowen, W. Jian, M. Lin, L. Meisheng, Y. Junshan, and S. Chengchao. 2002. A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor. J. Biol. Chem. 277:43137-43142.
15. Hjelle, B., F. Chavez-Giles, N. Torrez-Martinez, T. Yamada, J. Sarisky, M. Ascher, and S. Jenison. 1994. Dominant glycoprotein epitope of Four Corners hantavirus is conserved across a wide geographical area. J. Gen. Virol. 75:2881-2888.
16. Hlavacek, W. S., R. G. Posner, and A. S. Perelson. 1999. Steric effects on multivalent ligand-receptor binding: exclusion of ligand sites by bound cell surface receptors. Biophys. J. 76:3031-3043.
17. Huang, L., D. J. Sexton, K. Skogerson, M. Devlin, R. Smith, I. Sanyal, T. Parry, R. Kent, J. Enright, Q. L. Wu, G. Conley, D. DeOliveira, L. Morganelli, M. Ducar, C. R. Wescott, and R. C. Ladner. 2003. Novel peptide inhibitors of angiotensin-converting enzyme 2. J. Biol. Chem. 278:15532-15540.
18. Jenison, S., T. Yamada, C. Morris, B. Anderson, N. Torrez-Martinez, N. Keller, and B. Hjelle. 1994. Characterization of human antibody responses to four corners hantavirus infections among patients with hantavirus pulmonary syndrome. J. Virol. 68:3000-3006.
19. Johnson, C. M., R. Pandey, S. Sharma, G. K. Khuller, R. J. Basaraba, I. M. Orme, and A. J. Lenaerts. 2005. Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49:4335-4338.
20. Jonsson, C. B., and C. S. Schmaljohn. 2001. Replication of hantaviruses. Curr. Top. Microbiol. Immunol. 256:15-32.
21. Kane, R. S., and A. D. Stroock. 2007. Nanobiotechnology: protein-nanomaterial interactions. Biotechnol. Prog. 23:316-319.
22. Kingery-Wood, J. E., K. W. Williams, G. B. Sigal, and G. M. Whitesides. 1992. The agglutination of erythrocytes by influenza virus is strongly inhibited by liposomes incorporating an analog of sialyl gangliosides. J. Am. Chem. Soc. 114:7303-7305.
23. Kitov, P. I., J. M. Sadowska, G. Mulvey, G. D. Armstrong, H. Ling, N. S. Pannu, R. J. Read, and D. R. Bundle. 2000. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 403:669-672.
24. Kohane, D. S. 2007. Microparticles and nanoparticles for drug delivery. Biotechnol. Bioeng. 96:203-209.
25. Kreuter, J. (ed). 1994. Colloidal drug delivery systems, p. 219-342. Marcel Dekker, New York, NY.
26. 3-integrin receptor. J. Virol. 79:7319-7326.
27. Lawless, M. K., S. Barney, K. I. Guthrie, T. B. Bucy, S. R. Petteway, Jr., and G. Merutka. 1996. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. Biochemistry 35:13697-13708.
28. Limal, D., J. P. Briand, P. Dalbon, and M. Jolivet. 1998. Solid-phase synthesis and on-resin cyclization of a disulfide bond peptide and lactam analogues corresponding to the major antigenic site of HIV gp41 protein. J. Pept. Res. 52:121-129.
29. Lori, F., S. A. Calarota, and J. Lisziewicz. 2007. Nanochemistry-based immunotherapy for HIV-1. Curr. Med. Chem. 14:1911-1919.
30. Mackow, E. R., and I. N. Gavrilovskaya. 2001. Cellular receptors and hantavirus pathogenesis. Curr. Top. Microbiol. Immunol. 256:91-115.
31. Mammen, M., S. K. Choi, and G. M. Whitesides. 1998. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Ed. 37:2755-2794.
32. Mammen, M., G. Dahmann, and G. M. Whitesides. 1995. Effective inhibitors of hemagglutination by influenza virus synthesized from polymers having active ester groups. Insight into mechanism of inhibition. J. Med. Chem. 38:4179-4190.
33. Mammen, M., K. Helmerson, R. Kishore, S. K. Choi, W. D. Phillips, and G. M. Whitesides. 1996. Optically controlled collisions of biological objects to evaluate potent polyvalent inhibitors of virus-cell adhesion. Chem. Biol. 3:757-763.
34. Mohanraj, V. J., and Y. Chen. 2006. Nanoparticles - a review. Trop. J. Pharm. Res. 5:561-573.
35. Montet, X., M. Funovics, K. Montet-Abou, R. Weissleder, and L. Josephson. 2006. Multivalent effects of RGD peptides obtained by nanoparticle display. J. Med. Chem. 49:6087-6093.
36. Needleman, S. B., and C. D. Wunsch. 1970. A general method applicable to the search for similarities in the amino acid sequence of two proteins. J. Mol. Biol. 48:443-453.
37. Pandey, R., S. Sharma, and G. K. Khuller. 2006. Chemotherapeutic efficacy of nanoparticle encapsulated antitubercular drugs. Drug Deliv. 13:287-294.
38. Perez, E. 2005. New antitubulin agents. Proceedings of the 22nd Annual Miami Breast Cancer Conference, Miami, FL.
39. Prescott, J., P. R. Hall, V. S. Bondu-Hawkins, C. Ye, and B. Hjelle. 2007. Early innate immune responses to Sin Nombre hantavirus occur independently of IFN regulatory factor 3, characterized pattern recognition receptors, and viral entry. J. Immunol. 179:1796-1801.
40. Prescott, J., C. Ye, G. Sen, and B. Hjelle. 2005. Induction of innate immune response genes by Sin Nombre hantavirus does not require viral replication. J. Virol. 79:15007-15015.
41. Raymond, T., E. Gorbunova, I. N. Gavrilovskaya, and E. R. Mackow. 2005. Pathogenic hantaviruses bind plexin-semaphorin-integrin domains present at the apex of inactive, bent alphavbeta3 integrin conformers. Proc. Natl. Acad. Sci. USA 102:1163-1168.
42. Reuter, J. D., A. Myc, M. M. Hayes, Z. Gan, R. Roy, D. Qin, R. Yin, L. T. Piehler, R. Esfand, D. A. Tomalia, and J. R. Baker, Jr. 1999. Inhibition of viral adhesion and infection by sialic-acid-conjugated dendritic polymers. Bioconjug. Chem. 10:271-278.
43. Rosa, B. A., and C. L. Schengrund. 2005. Dendrimers and antivirals: a review. Curr. Drug Targets Infect. Disord. 5:247-254.
44. Shannon, J. P., M. V. Silva, D. C. Brown, and R. S. Larson. 2001. Novel cyclic peptide inhibits intercellular adhesion molecule-1-mediated cell aggregation. J. Pept. Res. 58:140-150.
45. Sillerud, L. O., and R. S. Larson. 2005. Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction. Curr. Protein Pept. Sci. 6:151-169.
46. Sinha, R., G. J. Kim, S. Nie, and D. M. Shin. 2006. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther. 5:1909-1917.
47. Spevak, W., J. O. Nagy, D. H. Charych, M. E. Scaefer, J. H. Gilbert, and M. D. Bednarski. 1993. Polymerized liposomes containing C-glycosides of sialic acid: potent inhibitors of influenza virus in vitro infectivity. J. Am. Chem. Soc. 115:1146-1147.
48. Tischler, N. D., A. Gonzalez, T. Perez-Acle, M. Rosemblatt, and P. D. Valenzuela. 2005. Hantavirus Gc glycoprotein: evidence for a class II fusion protein. J. Gen. Virol. 86:2937-2947.
49. Xiong, J. P., T. Stehle, S. L. Goodman, and M. A. Arnaout. 2004. A novel adaptation of the integrin PSI domain revealed from its crystal structure. J. Biol. Chem. 279:40252-40254.
50. Youssef, M., E. Fattal, M. J. Alonso, L. Roblot-Treupel, J. Sauzieres, C. Tancrede, A. Omnes, P. Couvreur, and A. Andremont. 1988. Effectiveness of nanoparticle-bound ampicillin in the treatment of Listeria monocytogenes infection in athymic nude mice. Antimicrob. Agents Chemother. 32:1204-1207.
51. Zahr, A. S., C. A. Davis, and M. V. Pishko. 2006. Macrophage uptake of core-shell nanoparticles surface modified with poly(ethylene glycol). Langmuir 22:8178-8185.